Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 14/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL14716442 | 0.86 | SMO (0.57) | SMOALDH1A1CYP1A2CYP3A4MAPT | |
| SCHEMBL14716258 | 0.84 | SMO (0.69) | SMONPC1RAB9AFAAH | |
| SCHEMBL1458893 | 0.81 | SMO (0.72) | SMO | |
| SCHEMBL1458341 | 0.79 | RAB9A (0.53) | ALDH1A1CYP1A2CYP3A4MAPTCYP2C9 | |
| Trifluoroacetic Acid SCHEMBL2158204 | 0.75 | SMO (0.90) | SMO | |
| Trifluoroacetic Acid SCHEMBL14716245 | 0.71 | SMO (0.61) | SMOSMN1; SMN2NPC1RAB9AFAAH | |
| Trifluoroacetic Acid SCHEMBL1458902 | 0.71 | RAB9A (0.48) | SMOALDH1A1CYP1A2CYP3A4MAPT | |
| Hydrochloric Acid SCHEMBL1458339 | 0.68 | KDM4E (0.54) | ALDH1A1CYP1A2CYP3A4MAPTHTT | |
| SCHEMBL14716443 | 0.68 | SMN1; SMN2 (0.42) | SMOALDH1A1CYP1A2CYP3A4MAPT | |
| Trifluoroacetic Acid SCHEMBL1459243 | 0.67 | SMO (0.63) | SMOSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053396-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-02-28 | — | — | US | claimed |
| US-20130053396-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053396-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS | SHH, SMO, GLI1 | SMO 2/4885ALDH1A1 876/4885CYP1A2 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.